Physician profile
Stacey Ice
NPI 1861845786
$7,878.83
in general payments reported to CMS, 2019-2025
32 companies · $983 in 2025
The $983 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $1,555 · 2023: $3,878 · 2024: $1,197 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,862 · Travel and Lodging: $1,195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.31 |
| Travel and Lodging | $1,195.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,547.03 | 2022-2025 | Vanta Adaptivestim, Intellis Adaptivestim, Inceptiv |
| Nevro Corp. | $848.68 | 2022-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $772.00 | 2021-2025 | Relistor |
| Pfizer INC. | $318.24 | 2021-2024 | |
| Abbvie INC. | $284.42 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $236.34 | 2022-2024 | Ztlido |
| Globus Medical, INC. | $225.73 | 2025 | Senza |
| Relievant Medsystems, INC. | $181.19 | 2021-2023 | Intracept |
| Nalu Medical, INC. | $157.61 | 2023-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $131.82 | 2021-2024 | Wavewriter Alpha Prime 16 |
| Stryker Corporation | $130.28 | 2025 | Mild Device Kit |
| Merz Pharmaceuticals, LLC | $114.73 | 2023-2025 | Xeomin |
| Biohaven Pharmaceutical Holding Company LTD. | $108.80 | 2022 | |
| Spinal Simplicity, LLC | $92.25 | 2023 | Ha Minuteman G3-R |
| Bioventus LLC | $74.98 | 2024-2025 | Durolane |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $73.04 | 2021-2025 | Xtampza |
| Grt US Holding, INC. | $67.12 | 2021-2022 | |
| Averitas Pharma INC. | $63.25 | 2023-2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $62.66 | 2022-2023 | Ajovy |
| Mml US, INC. | $52.01 | 2023-2025 | Reactiv8 |
| Spr Therapeutics, INC | $52.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $46.20 | 2025 | |
| Fidia Pharma USA INC. | $40.05 | 2023 | Hymovis |
| Abbott Laboratories | $34.16 | 2021 | |
| Masimo Corporation | $31.93 | 2024 | Set and Rainbow Set |
| Biodelivery Sciences International, INC. | $29.23 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $24.82 | 2023 | Iovera, Zilretta |
| Horizon Therapeutics Plc | $19.78 | 2022 | |
| Valinor Pharma, LLC | $16.19 | 2025 | Movantik |
| Arbor Pharmaceuticals, INC. | $16.03 | 2021 | |
| Protega Pharmaceutials INC | $14.28 | 2023 | Roxybond |
| Almatica Pharma LLC | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Ice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.